Clinical Trials Sponsored by Hapten Sciences, Inc.

Total 1473 results

Hapten Sciences, Inc.

Completed

A Phase I, Single-Center Study of PDC-APB in Healthy Volunteers

Contact Dermatitis

United States
Hapten Sciences, Inc.
Milton S. Hershey Medical Center

Not yet recruiting

A Safety, Tolerability, and Dermal Reactogenicity Study of PDC-APB

Contact Dermatitis
Santen Inc.

Completed

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study

Glaucoma and Ocular Hypertension

United States
Santen Inc.

Completed

Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects

Age-Related Macular Degeneration

United States, Philippines
Santen Inc.

Completed

A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program (SPRING)

Non-Infectious Uveitis of the Posterior Segment of the Eye

United States, France, Turkey, Italy, Austria, India
Santen Inc.

Completed

Study Assessing Double-masked Uveitis Treatment (SAKURA)

Uveitis; Posterior, Disorder

United States, France, Italy, Poland, United Kingdom, Germany, Spain, Austria, Colombia, Israel, India, Turkey, Japan, Peru, Argentina, Brazil, Chile
Santen Inc.

Completed

A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration (VAPOR1)

Age-Related Macular Degeneration

United States
Santen Inc.

Completed

Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Dry Eye

United States
Santen Inc.

Completed

DE-117 Spectrum 5 Study

Primary Open-angle Glaucoma and Ocular Hypertension

United States
Santen Inc.

Completed

Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia (OPSIS)

Presbyopia

United States
Santen Inc.

Completed

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

Glaucoma and Ocular Hypertension

United States
Santen Inc.

Completed

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension (ANGEL-2)

Primary Open Angle Glaucoma | Ocular Hypertension

United States
Santen Inc.

Completed

A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration (PAVE)

Age-Related Macular Degeneration

United States
Santen Inc.

Completed

Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SEE-1)

Ocular Hypertension | Open-angle Glaucoma

United States
Santen Inc.

Completed

Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Open-angle Glaucoma or Ocular Hypertension

United States
Santen Inc.

Completed

A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration

Age-Related Macular Degeneration

United States
Santen Inc.

Completed

A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT

Glaucoma and Ocular Hypertension

United States
Santen Inc.

Completed

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States
Santen Inc.

Completed

Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators

Healthy

United States
Santen Inc.

Terminated

LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

Non Infectious Uveitis

United States, India, Italy, Argentina
Santen Inc.

Completed

A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

Open-angle Glaucoma, Ocular Hypertension

United States, Japan
Santen Inc.

Completed

Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6

Primary Open-angle Glaucoma and Ocular Hypertension

United States
Santen Inc.

Completed

Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease

Dry Eye

United States
Santen Inc.

Completed

A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Dry Eye Disease

United States
Santen Inc.

Completed

Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

United States
Santen Inc.

Completed

Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States
Santen Inc.
MacuSight, Inc.

Completed

Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema

Diabetic Macular Edema

United States
Santen Inc.
MacuSight, Inc.

Completed

Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

Diabetic Retinopathy | Diabetic Macular Edema

United States
Santen Inc.
MacuSight, Inc.

Completed

A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model

Dry Eye

United States
Santen Inc.
MacuSight, Inc.

Terminated

Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration

Age-related Macular Degeneration | Choroidal Neovascularization

United States
Santen Inc.
MacuSight, Inc.

Terminated

Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration (EMERALD)

Age-Related Macular Degeneration | Choroidal Neovascularization

United States
Santen Inc.
ActualEyes Inc.

Recruiting

A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) (PHANTOM)

Fuchs Endothelial Corneal Dystrophy

United States
Zhengzhou Gensciences Inc
Haimen Gensciences lnc

Completed

An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.

Hemophilia A

China
Halucenex Life Sciences Inc.
KGK Science Inc.

Active, not recruiting

Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder

Post Traumatic Stress Disorder | Treatment Resistant Disorders

Canada
Santen Inc.
Vistakon Pharmaceuticals

Terminated

Ocular Penetration of 1.5% Levofloxacin and 0.5% Moxifloxacin During Corneal Transplant Surgery

Corneal Transplantation

United States
Stanford University
Santen Inc.

Withdrawn

Intravitreal Sirolimus as Therapeutic Approach to Uveitis (SAVE-2)

Panuveitis | Uveitis | Posterior Uveitis | Intermediate Uveitis

United States
USANA Health Sciences
KGK Science Inc.

Completed

Effect of a MVM Dietary Supplement on Indices of Human Health

Metabolic Syndrome

Canada
Santen Inc.
Vistakon Pharmaceuticals

Completed

Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator

Cataract

United States
New Haven Pharmaceuticals, Inc.

Completed

Length of Effect of Extended Release Aspirin on Platelets in Patients With Diabetes and Heart Disease (DURATION)

Cardiovascular Disease

United States
SK Life Science, Inc.
PRA Health Sciences

Completed

Bioavailability and Food Effect Study of 3 Types of Carisbamate

Healthy Subjects

United States
IC-IT Sciences Inc.

Unknown

Comparison of the Natural Frequencies Technology Sleep Patches to Sham Patches During Sleep in the Home Environment

Sleep Disturbance

United States
The Cleveland Clinic
Santen Inc.

Active, not recruiting

Imaging Quantification of Inflammation (IQI) (IQI)

Uveitis

United States
Lithuanian University of Health Sciences
Santen Oy

Recruiting

The Pattern of Dry Eye Disease After Cataract Surgery

Cataract | Ocular Surface Disease | Dry Eye Disease

Lithuania
Natural Immune Systems Inc
New Chapter Inc.

Completed

Golden Black Seed: Support of Metabolic Health and General Wellness.

Hyperglycemia | Hyperlipidemias

United States
Integrative Skin Science and Research
AgeLess Sciences Inc.

Active, not recruiting

The Effects of a Longevity Supplement on Aging and Photoaging

Photoaging

United States
TriHealth Inc.
TriHealth Hatton Research Institute

Completed

Detection Rate of Serrated Adenomas in Screening Colonoscopy

Healthy Patients Undergoing Screening Colonoscopy

United States
TriHealth Inc.
TriHealth Hatton Research Institute

Completed

Clitoral Location in Relation to Sexual Function Using Pelvic Imaging

Female Sexual Dysfunction | Anorgasmia

United States
Kodiak Sciences Inc

Recruiting

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR) (GLOW2)

Non-proliferative Diabetic Retinopathy

United States, Puerto Rico
Cassava Sciences, Inc.

Not yet recruiting

Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects

Evaluate the Absorption, Metabolism, and Excretion of [ 14C]-Simufilam
Translational Sciences, Inc.

Recruiting

Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial (NAIL-IT)

Pulmonary Embolism

United States

3

Subscribe